Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 20% in the afternoon, surged more than 30% in the two days after opening, and the global AI+ mRNA vaccine circuit accelerated

The Zhitong Finance App learned that Jitai Technology-P (07666) rose more than 20% in the afternoon, and the cumulative increase over the two days of entry had already exceeded 30%. As of press release, it rose 17.07% to HK$18.04, with a turnover of HK$313 million.

According to the news, on September 7, Jietai Technology-P was officially transferred to the Hong Kong Stock Connect securities list, which means that mainland investors can now directly trade Jetai Technology through the Shanghai-Shenzhen-Hong Kong Stock Connect to officially unlock southbound capital. The Board believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share transactions.

Notably, Moderna's previous breakthrough in the “cancer vaccine” ignited the AI+ mRNA circuit. At present, Jietai Technology has opened up the entire chain of AI molecular design, RNA code optimization, and accurate LNP delivery to accurate clinical implementation. The potential transaction scale for related cutting-edge therapies has reached the level of 6 billion yuan. The mRNA tumor vaccine pipeline also has plans to continue to expand, and the commercialization growth rate is likely to far exceed industry expectations. Furthermore, the commercialization results of Jietai Technology's NanoForge have entered a centralized release period.